Fig 1.
Trial profile, showing the number of children in each zone in the stepped-wedge trial.
Fig 2.
Map of the study area showing health facilities involved in SMC delivery and pharmacovigilance.
Table 1.
Source of drugs, and dosage by age, in each year.
Table 2.
No. of children who received the first daily dose of SMC treatment*.
Table 3.
Causes of death determined by verbal autopsy among children eligible for SMC (i.e. aged 3–59 months in 2008 and aged 3–119 months in 2009 and 2010) in the areas served by 12 health post.
Fig 3.
Adverse drug reactions notified by health facilities within 10 days of SMC administration.
The incidence as the percentage of children who were treated is indicated on the left hand axis) and number of cases on the right hand axis). In 2009, the total number of adverse event reports was 33% (95% CI 19%,45%) lower in October than in September and 69% (95% CI 61%,76%) lower in November than in September. In 2010 the number of adverse events was 35% (95% CI 25%,44%) lower in October than in September, and in 70% (95% CI 64%,75%) lower in November.
Fig 4.
Age distribution of cases (upper left); time from the first SMC dose to onset of symptoms (upper right); duration of symptoms (lower left) and frequency of vomiting (lower right) in 108 children who presented at the clinic with symptoms of vomiting within 1 week of SMC administration.
Table 4.
Incidence of mild adverse reactions to SMC reported to health posts in 2010.